Overview

A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Otsuka Novel Products GmbH